Key result
Intravenous treprostinil administered from 25 weeks gestation in a pregnant woman with pulmonary hypertension resulted in a successful delivery at 33 weeks and favorable maternal and fetal outcomes.
Why the study?
Does intravenous treprostinil improve maternal and fetal outcomes in a pregnant woman with pulmonary hypertension?
Case Report (n=1)
No
Does intravenous treprostinil improve maternal and fetal outcomes in a pregnant woman with pulmonary hypertension?
Intravenous treprostinil can be successfully used as part of an intensive therapeutic protocol to manage pulmonary hypertension during pregnancy, leading to favorable maternal and fetal outcomes.
Adds to sparse case reports of IV treprostinil in pregnant PH; hypothesis-generating and should not yet change practice.
Pulmonary hypertension (PH) presents a high risk for maternal mortality. The intravenous administration of treprostinil has demonstrated effectiveness for the treatment of PH, though documentations of its use during pregnancy are few. The authors present a 30-year-old gravid women with symptoms of PH at 23 weeks gestation. Treatment comprised of oxygen therapy, enoxaparin, and intravenous treprostinil from gestational week 25, following a successful elective cesarean section at 33 weeks gestation with favorable outcome. This report demonstrates the effectiveness of an intensive therapeutic protocol, including intravenous treprostinil, for the treatment of PH in pregnancy.
No takes yet. Share an insight, caveat, or question.
Rosengarten et al. (2015) conducted a case report in Pulmonary hypertension in pregnancy (n=1). Intravenous treprostinil was evaluated on Maternal and fetal outcome. Intravenous treprostinil administered from 25 weeks gestation in a pregnant woman with pulmonary hypertension resulted in a successful delivery at 33 weeks and favorable maternal and fetal outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: